-
1
-
-
79958754972
-
Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence
-
Azoulay L, Dell'Aniello S, Huiart L, du Fort GG, Suissa S (2011) Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat 126(3): 695-703
-
(2011)
Breast Cancer Res Treat
, vol.126
, Issue.3
, pp. 695-703
-
-
Azoulay, L.1
Dell'Aniello, S.2
Huiart, L.3
Du Fort, G.G.4
Suissa, S.5
-
2
-
-
33747045564
-
Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: Data from the Italian Tamoxifen Trial
-
Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, Travaglini R, Muraca MG, Rotmensz N, Veronesi U, Decensi AU (2006) Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 24(22): 3708-3709
-
(2006)
J Clin Oncol
, vol.24
, Issue.22
, pp. 3708-3709
-
-
Bonanni, B.1
MacIs, D.2
Maisonneuve, P.3
Johansson, H.A.4
Gucciardo, G.5
Oliviero, P.6
Travaglini, R.7
Muraca, M.G.8
Rotmensz, N.9
Veronesi, U.10
Decensi, A.U.11
-
3
-
-
33745347897
-
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment
-
Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80(1): 61-74
-
(2006)
Clin Pharmacol Ther
, vol.80
, Issue.1
, pp. 61-74
-
-
Borges, S.1
Desta, Z.2
Li, L.3
Skaar, T.C.4
Ward, B.A.5
Nguyen, A.6
Jin, Y.7
Storniolo, A.M.8
Nikoloff, D.M.9
Wu, L.10
Hillman, G.11
Hayes, D.F.12
Stearns, V.13
Flockhart, D.A.14
-
4
-
-
68749113944
-
Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The 'personalised' approach?
-
Brauch H, Jordan VC (2009) Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? Eur J Cancer 45(13): 2274-2283
-
(2009)
Eur J Cancer
, vol.45
, Issue.13
, pp. 2274-2283
-
-
Brauch, H.1
Jordan, V.C.2
-
5
-
-
80052059849
-
First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial
-
IBIS investigators
-
Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T, IBIS investigators (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360(9336): 817-824
-
(2002)
Lancet
, vol.360
, Issue.9336
, pp. 817-824
-
-
Cuzick, J.1
Forbes, J.2
Edwards, R.3
Baum, M.4
Cawthorn, S.5
Coates, A.6
Hamed, A.7
Howell, A.8
Powles, T.9
-
6
-
-
33847793068
-
Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial
-
International Breast Cancer Intervention Study I Investigators
-
Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, International Breast Cancer Intervention Study I Investigators (2007) Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99(4): 272-282
-
(2007)
J Natl Cancer Inst
, vol.99
, Issue.4
, pp. 272-282
-
-
Cuzick, J.1
Forbes, J.F.2
Sestak, I.3
Cawthorn, S.4
Hamed, H.5
Holli, K.6
Howell, A.7
-
7
-
-
56449112123
-
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial
-
ATAC Trialists' Group
-
Cuzick J, Sestak I, Cella D, Fallowfield L, ATAC Trialists' Group (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12): 1143-1148
-
(2008)
Lancet Oncol
, vol.9
, Issue.12
, pp. 1143-1148
-
-
Cuzick, J.1
Sestak, I.2
Cella, D.3
Fallowfield, L.4
-
8
-
-
4243063941
-
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
-
Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310(3): 1062-1075
-
(2004)
J Pharmacol Exp Ther
, vol.310
, Issue.3
, pp. 1062-1075
-
-
Desta, Z.1
Ward, B.A.2
Soukhova, N.V.3
Flockhart, D.A.4
-
9
-
-
33847034287
-
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
-
Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101(1): 113-121
-
(2007)
Breast Cancer Res Treat
, vol.101
, Issue.1
, pp. 113-121
-
-
Goetz, M.P.1
Knox, S.K.2
Suman, V.J.3
Rae, J.M.4
Safgren, S.L.5
Ames, M.M.6
Visscher, D.W.7
Reynolds, C.8
Couch, F.J.9
Lingle, W.L.10
Weinshilboum, R.M.11
Fritcher, E.G.12
Nibbe, A.M.13
Desta, Z.14
Nguyen, A.15
Flockhart, D.A.16
Perez, E.A.17
Ingle, J.N.18
-
10
-
-
33644639136
-
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
-
Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23(36): 9312-9318
-
(2005)
J Clin Oncol
, vol.23
, Issue.36
, pp. 9312-9318
-
-
Goetz, M.P.1
Rae, J.M.2
Suman, V.J.3
Safgren, S.L.4
Ames, M.M.5
Visscher, D.W.6
Reynolds, C.7
Couch, F.J.8
Lingle, W.L.9
Flockhart, D.A.10
Desta, Z.11
Perez, E.A.12
Ingle, J.N.13
-
11
-
-
70349575970
-
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort
-
Consortium on Breast Cancer Pharmacogenomics Investigators
-
Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, Stearns V, Consortium on Breast Cancer Pharmacogenomics Investigators. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort (2009) Breast Cancer Res Treat 117(3): 571-575
-
(2009)
Breast Cancer Res Treat
, vol.117
, Issue.3
, pp. 571-575
-
-
Henry, N.L.1
Rae, J.M.2
Li, L.3
Azzouz, F.4
Skaar, T.C.5
Desta, Z.6
Sikora, M.J.7
Philips, S.8
Nguyen, A.T.9
Storniolo, A.M.10
Hayes, D.F.11
Flockhart, D.A.12
Stearns, V.13
-
12
-
-
76749143669
-
CYP2D6 polymorphisms and tamoxifen metabolism: Clinical relevance
-
Higgins M J, Stearns V (2010) CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep 12(1): 7-15
-
(2010)
Curr Oncol Rep
, vol.12
, Issue.1
, pp. 7-15
-
-
Higgins, M.J.1
Stearns, V.2
-
13
-
-
43649090742
-
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy
-
Kiyotani K, Mushiroda T, Sasa M, Bando Y, Sumitomo I, Hosono N, Kubo M, Nakamura Y, Zembutsu H (2008) Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 99(5): 995-999
-
(2008)
Cancer Sci
, vol.99
, Issue.5
, pp. 995-999
-
-
Kiyotani, K.1
Mushiroda, T.2
Sasa, M.3
Bando, Y.4
Sumitomo, I.5
Hosono, N.6
Kubo, M.7
Nakamura, Y.8
Zembutsu, H.9
-
14
-
-
34548532227
-
Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer
-
Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J (2007) Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 25(25): 3837-3845
-
(2007)
J Clin Oncol
, vol.25
, Issue.25
, pp. 3837-3845
-
-
Lim, H.S.1
Ju Lee, H.2
Seok Lee, K.3
Sook Lee, E.4
Jang, I.J.5
Ro, J.6
-
15
-
-
41149083559
-
Tamoxifen, hot flashes and recurrence in breast cancer
-
WHEL Study Group
-
Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, Pierce JP, WHEL Study Group (2008) Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108(3): 421-426
-
(2008)
Breast Cancer Res Treat
, vol.108
, Issue.3
, pp. 421-426
-
-
Mortimer, J.E.1
Flatt, S.W.2
Parker, B.A.3
Gold, E.B.4
Wasserman, L.5
Natarajan, L.6
Pierce, J.P.7
-
16
-
-
21344467511
-
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients
-
Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, MacLeod SL, Kadlubar FF, Ambrosone CB (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91(3): 249-258
-
(2005)
Breast Cancer Res Treat
, vol.91
, Issue.3
, pp. 249-258
-
-
Nowell, S.A.1
Ahn, J.2
Rae, J.M.3
Scheys, J.O.4
Trovato, A.5
Sweeney, C.6
MacLeod, S.L.7
Kadlubar, F.F.8
Ambrosone, C.B.9
-
17
-
-
84859054082
-
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients
-
ATAC trialists
-
Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M, ATAC trialists (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104(6): 452-460
-
(2012)
J Natl Cancer Inst
, vol.104
, Issue.6
, pp. 452-460
-
-
Rae, J.M.1
Drury, S.2
Hayes, D.F.3
Stearns, V.4
Thibert, J.N.5
Haynes, B.P.6
Salter, J.7
Sestak, I.8
Cuzick, J.9
Dowsett, M.10
-
18
-
-
84859093970
-
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial
-
Collaborative Group
-
Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G Collaborative Group (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104(6): 441-451
-
(2012)
J Natl Cancer Inst
, vol.104
, Issue.6
, pp. 441-451
-
-
Regan, M.M.1
Leyland-Jones, B.2
Bouzyk, M.3
Pagani, O.4
Tang, W.5
Kammler, R.6
Dell'Orto, P.7
Biasi, M.O.8
Thürlimann, B.9
Lyng, M.B.10
Ditzel, H.J.11
Neven, P.12
Debled, M.13
Maibach, R.14
Price, K.N.15
Gelber, R.D.16
Coates, A.S.17
Goldhirsch, A.18
Rae, J.M.19
Viale, G.20
more..
-
19
-
-
36349024762
-
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
-
Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25(33): 5187-5193
-
(2007)
J Clin Oncol
, vol.25
, Issue.33
, pp. 5187-5193
-
-
Schroth, W.1
Antoniadou, L.2
Fritz, P.3
Schwab, M.4
Muerdter, T.5
Zanger, U.M.6
Simon, W.7
Eichelbaum, M.8
Brauch, H.9
-
20
-
-
33748440400
-
Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms
-
Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J (2006) Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol 24(24): 3991-3996
-
(2006)
J Clin Oncol
, vol.24
, Issue.24
, pp. 3991-3996
-
-
Sestak, I.1
Kealy, R.2
Edwards, R.3
Forbes, J.4
Cuzick, J.5
-
21
-
-
1842680082
-
A breast cancer prediction model incorporating familial and personal risk factors
-
Tyrer J, Duffy S W, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7): 1111-1130
-
(2004)
Stat Med
, vol.23
, Issue.7
, pp. 1111-1130
-
-
Tyrer, J.1
Duffy, S.W.2
Cuzick, J.3
-
22
-
-
34249732092
-
Tamoxifen for the prevention of breast cancer: Late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy
-
Italian Tamoxifen Study Group
-
Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Oliviero P, Lovison F, Gucciardo G, del Turco MR, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Italian Tamoxifen Study Group (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99(9): 727-737
-
(2007)
J Natl Cancer Inst
, vol.99
, Issue.9
, pp. 727-737
-
-
Veronesi, U.1
Maisonneuve, P.2
Rotmensz, N.3
Bonanni, B.4
Boyle, P.5
Viale, G.6
Costa, A.7
Sacchini, V.8
Travaglini, R.9
D'Aiuto, G.10
Oliviero, P.11
Lovison, F.12
Gucciardo, G.13
Del Turco, M.R.14
Muraca, M.G.15
Pizzichetta, M.A.16
Conforti, S.17
Decensi, A.18
-
23
-
-
20244363902
-
Italian randomized trial among women with hysterectomy: Tamoxifen and hormone-dependent breast cancer in high-risk women
-
Italian Tamoxifen Study Group
-
Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Robertson C, Boyle P, Italian Tamoxifen Study Group (2003) Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95(2): 160-165
-
(2003)
J Natl Cancer Inst
, vol.95
, Issue.2
, pp. 160-165
-
-
Veronesi, U.1
Maisonneuve, P.2
Rotmensz, N.3
Costa, A.4
Sacchini, V.5
Travaglini, R.6
D'Aiuto, G.7
Lovison, F.8
Gucciardo, G.9
Muraca, M.G.10
Pizzichetta, M.A.11
Conforti, S.12
Decensi, A.13
Robertson, C.14
Boyle, P.15
-
24
-
-
29144491089
-
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
-
Wegman P, Vainikka L, Stal O, Nordenskjöld B, Skoog L, Rutqvist LE, Wingren S (2005) Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7(3): R284-R290
-
(2005)
Breast Cancer Res
, vol.7
, Issue.3
-
-
Wegman, P.1
Vainikka, L.2
Stal, O.3
Nordenskjöld, B.4
Skoog, L.5
Rutqvist, L.E.6
Wingren, S.7
-
25
-
-
47749105202
-
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment
-
Xu Y, Sun Y, Yao L, Shi L,Wu Y, Ouyang T, Li J,Wang T, Fan Z, Fan T, Lin B, He L, Li P, Xie Y (2008) Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 19(8): 1423-1429
-
(2008)
Ann Oncol
, vol.19
, Issue.8
, pp. 1423-1429
-
-
Xu, Y.1
Sun, Y.2
Yao, L.3
Shi Lwu, Y.4
Ouyang, T.5
Li Jwang, T.6
Fan, Z.7
Fan, T.8
Lin, B.9
He, L.10
Li, P.11
Xie, Y.12
|